SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Value Investing
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Paul Senior who wrote (17947)10/31/2003 8:27:24 PM
From: Spekulatius  Read Replies (1) of 78430
 
Re JNJ and other drug stocks -
It seems that i have been a little to fast to sell my JNJ position, its up 2% from where I sold. Still the stent new is worrysome and together with the other negatives (erosion of Procrit sales due to competition with Amgen), excellent stent testing results from BSX i decided that enough is enough. I will watch for more news and possibly build a position again.

I see that MRK is doing badly, it finally is common knowledge that MRK has problem due to patent expiration and thin pipeline. They have only 3 drugs or so in PhIII which is abysmal for a drug company of MRK's size. I would still avoid this stock at current prices (44$).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News